Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Background Histologically assessed liver fibrosis stage has prognostic significance in
patients with non-alcoholic fatty liver disease (NAFLD) and is accepted as a surrogate …

Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …

This Practice Guidance from the American Association for the Study of Liver Disease
(AASLD) intends to coalesce best practice recommendations for the identification of portal …

Chronic liver disease (CLD) is associated with approximately two million annual deaths
worldwide and is an enormous health burden.[1, 2] The majority of liver-related outcomes …

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent form of chronic liver disease
that poses challenges in diagnosis and risk stratification. Non-alcoholic steatohepatitis …

Background Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease,
and among the non-invasive tests, controlled attenuation parameter (CAP) and liver stiffness …